(CercleFinance.com) – AstraZeneca gains nearly 1% in London, supported by an analysis by AlphaValue which announced on Monday that it has raised its opinion on the stock, which it is moving from ‘lighten’ to ‘accumulate’ with a goal price maintained at 12,896 pence.
In a note released in the morning, the independent research office highlights the strong growth recorded by the biopharmaceutical laboratory in oncology, as well as its new status as a ‘giant’ in the treatment of rare diseases.
Two areas that benefit from significant growth and high profit margins, argues the Parisian firm, which also salutes the solid execution of the group in terms of research and development (R&D).
In view of the “impressive” results obtained by its drug projects at the most advanced stage, AlphaValue is revising its earnings forecasts for the group upwards, which leads it to raise its opinion on the stock.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
